reports
Lord David Prior Appointed as Chair of e-therapeutics’ Board of Direct...
JP Jenkins Ltd Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors 23-May-2024 / 08:32 GMT/BST The issuer is solely responsible for the content of this announcement. 23rd May 2024 JPJ:ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or “ETX” or the "Company") Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors London, UK, 23 May 2024 – e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased announce the appointment...
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 9,000 shares at 915.500DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
e-therapeutics plc shares now trading on JP Jenkins
JP Jenkins Ltd e-therapeutics plc shares now trading on JP Jenkins 09-May-2024 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. 9th May 2024 JPJ: ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") Shares now trading on JP Jenkins London, UK, 9th May 2024 – e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces its shares (“ETX”) () have been admitted to trade on JP Jenkins share dealing plat...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Small guidance raise
Q1 LCY figures beat consensus due to US rebate adjustments related to 2023 adding c5%-points to LCY growth and low SG&A cost boosting EBIT growth in Q1. Wegovy sales were below consensus but above our forecast, and we have therefore adjusted our rebate assumptions for 2024. The 2024 guidance was raised to LCY sales growth of 19–27% (18–26%) and LCY operating profit growth of 22–30% (21–29%). We reiterate our BUY and DKK1,100 target price.
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Company consensus added
We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
- Sean Conroy
e-therapeutics - Termination of coverage
Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our web...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Ozempic to drive raised guidance
We are slightly below consensus on Q1 LCY sales growth (we forecast 19.4%, consensus 20.1%) and LCY operating profit growth (we forecast 16.8%, consensus 17.3%), due to lower expected Wegovy sales. However, we believe the trend in Ozempic US prescriptions will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Raising the bar with amycretin
At its CMD, the company maintained its strategic aspirations for 2025. It also expects increasing operating profit margins in the coming years. A key focus was the phase I trial results for amycretin in obesity, showing 13.1% weight loss (no signs of plateau). While not confirmed, we still expect it to go directly to phase III development. We reiterate our BUY and have increased our target price to DKK1,100 (1,000) on higher pipeline valuation.
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1000.00) - Catalent: game changer
We believe the move by Novo Holding to acquire Catalent and re-sell the three fill-finish facilities to Novo Nordisk is inspired, and underpins the strength of having the foundation as a major shareholder. With the acquisition, the obesity opportunity moves from supply to demand-driven, while at the same time making scale a significant competitive advantage. We have upgraded to BUY (HOLD) and raised our target price to DKK1,000 (800).
- Rune Majlund Dahl
Novo Nordisk (Hold, TP: DKK800.00) - Solid wide guidance
The wide 2024 guidance for local currency (LCY) growth of 18–26% for sales and 21–29% for operating profit reflects the uncertainty over supply and demand for Ozempic and Wegovy. Yet the sharp capex increase highlights confidence in the long-term growth outlook. We reiterate our HOLD but have raised our target price to DKK800 (750) on a solid Q4 result and outlook.
- Rune Majlund Dahl
Novo Nordisk (Hold, TP: DKK750.00) - Company consensus added
We forecast Q4 LCY sales growth of 36.4% YOY (consensus 37.0%) and LCY operating profit growth of 61.7% (consensus 58.5%). For Q4 Ozempic and Wegovy sales, we are well below consensus, with our calculations indicating consensus has included inventory build-up well above our forecasts. We expect 2024 guidance for 18–24% LCY sales growth and 22–28% LCY operating profit growth. We reiterate our HOLD and DKK750 target price.
- Rune Majlund Dahl
Novo Nordisk (Hold, TP: DKK750.00) - Likely below 2023 mid-point targe...
Based on US scripts, we believe LCY sales growth slowed in Q4 and forecast 2023 below the guidance mid-point of 33.9% YOY. Benefiting from product mix, we estimate 2023 LCY operating profit growth at the guidance mid-point. We expect 2024 guidance for 18–24% LCY sales growth and 22–28% LCY operating profit growth. We reiterate our HOLD and DKK750 target price.
- Martin Hall
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
- Rune Majlund Dahl
Novo Nordisk (Hold, TP: DKK750.00) - Higher US Wegovy rebate for 2024e
Data from the North Carolina Health Plan indicates a c9%-point higher US Wegovy rebate YOY for 2024. Thus, we have raised our 2024e US Wegovy rebate assumption from 50% to 53.6% and forecast global Wegovy sales of DKK57,955m (down c7% on unchanged prescription assumptions). We expect continued strong Ozempic momentum for 2024 and reported sales growth of c26% YOY. We reiterate our HOLD and DKK750 target price.
- Bruno Cavalier
- Martin Marandon-Carlhian
- Stephane Houri
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/13/2023
We are adding CaixaBank and Deutsche Börse to the ODDO BHF European Large Caps List. At the same time, we are removing Accor (market scepticism on the hotel sector, valuation drivers behind us) and Ryanair (same market scepticism on travel, very good Q3 results having already helped the stock rally). We are also downgrading the Travel & Leisure sector from Overweight to Market Weight. Since its creation, the ODDO BHF European Large Caps List has recorded a total return of +8.5% compar...
Edison issues update on e-therapeutics (ETX): More to come in RNAi the...
Edison Investment Research Limited Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery 13-Nov-2023 / 09:05 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 13 November 2023 Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop short interfering RNA (siRNA) therapies. The key half-year development was the pr...
- Bruno Cavalier
- Martin Marandon-Carlhian
- Stephane Houri
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/11/2023
Nous faisons entrer CaixaBank et Deutsche Börse dans notre liste de Valeurs recommandées Large Caps. Inversement, nous faisons sortir Accor (scepticisme du marché sur le secteur de l’hôtellerie, catalyseurs derrière nous) et Ryanair (même scepticisme du marché sur les voyages, les très bons résultats T3 ont permis le rebond du titre). Nous dégradons également le secteur du Travel & Leisure de Surpondérer à Neutre. Depuis sa création, notre liste enregistre un total return de +8,5% vs ...
EDEN EDENRED SA
DGE DIAGEO PLC
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SW SODEXO SA
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
SCR SCOR SE
ALV ALLIANZ SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
NOVO B NOVO NORDISK A/S CLASS B
KER KERING SA
VOE VOESTALPINE AG
01913 PRADA S.P.A.
BA. BAE SYSTEMS PLC
MONC MONCLER SPA
CFR COMPAGNIE FINANCIERE RICHEMONT SA
CLNX CELLNEX TELECOM S.A.
- Sean Conroy
e-therapeutics - More to come in RNAi therapy discovery
e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop short interfering RNA (siRNA) therapies. The key half-year development was the proof-of-concept (PoC) data for two preclinical assets for the treatment of cardiometabolic disease and haemophilia, with further updates forthcoming. We view these pipeline updates, especially in segments with increased interest, as positive. Management co...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : SELECT: results that justify a change in patient care
>Confirmation of Wegovy's role in cardiac protection for obese patients - At the AHA (American Heart Association) congress, Novo Nordisk recapped on the clinical results of its SELECT trial. Note that the objective of this trial was to demonstrate that, in patients suffering from obesity and cardiovascular disease without a history of diabetes, taking Wegovy improved cardiovascular function in this population (n=17,604). The primary endpoint was a composite (taking se...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : SELECT: des résultats qui justifient un changement de l...
>Confirmation de l’intérêt de Wegovy dans la protection cardiaque des obèses - Novo Nordisk est revenu, lors du congrès de l’AHA, sur les résultats cliniques de son essai nommé SELECT. Pour rappel, l’objectif de cet essai était de démontrer que la prise de Wegovy chez des patients souffrant d'obésité et d'une maladie cardiovasculaire sans antécédents de diabète améliorait la fonction cardio-vasculaire de cette population (n=17 604). Le critère primaire était un critèr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.